Painless Endoscopy
Conditions
Interventions
Experimental group:Pre-interventional sedation induction for gastroscopy: The initial intravenous dose of propofol is 0.4mg/kg, and the injection time should be no less than 30 seconds. One minute aft
if the subject's MOAA/S score is = 2 or the gastroscopy procedure fails after 2 minutes, additional propofol administration is allowed. During the entire period from administration to the completion o
Control group:Pre-introduction sedation induction for gastroscopy: The initial intravenous dose of propofol is 2.0mg/kg, and the infusion time should be no less than 30 seconds. One minute after the i
Sponsors
The First Affiliated Hospital of Wenzhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1) Age between 18 and 65 years old, gender not restricted; 2) BMI >= 24 kg/m^2 (according to the BMI standard for Asians); 3) Patients who have undergone gastroscopy treatment in our hospital; 4) ASA classification as Grade I or Grade II; 5) Clearly understand and voluntarily participate in this study, and sign the informed consent form by themselves or their family members.
Exclusion criteria
Exclusion criteria: 1) Complex endoscopic procedures are required; 2) Patients with a history of allergy or hypersensitivity to soy or egg products, opioids, and any other anesthetic agents; 3) Patients with a history of drug or alcohol abuse in the past 3 months; 4) Patients with severe cardiovascular diseases: uncontrolled hypertension (systolic blood pressure >= 170 mmHg, diastolic blood pressure >= 105 mmHg, without using antihypertensive drugs); severe arrhythmia; heart failure; Adams-Stokes syndrome; unstable angina pectoris; myocardial infarction within 6 months; third-degree atrioventricular block or QTcF interval >= 450 ms; 5) Patients with severe respiratory diseases: respiratory insufficiency; chronic obstructive pulmonary disease; bronchospasm requiring treatment within 3 months; acute respiratory infection with obvious fever, wheezing, nasal congestion, cough within 1 week; 6) Patients with cerebrovascular diseases: brain injury, convulsions, intracranial hypertension, cerebral aneurysm; 7) Patients with mental disorders: schizophrenia, mania, etc.; 8) Patients with severe gastrointestinal diseases: gastric retention; continuous bleeding; 9) Pregnant or lactating women; 10) Patients who have participated in any other clinical trials within 30 days; 11) Patients who cannot communicate well with the researchers; 12) Patients considered unsuitable to participate in this study by the researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of hypoxemia;Incidence of respiratory depression;Incidence of apnea; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of hypotension;Incidence of nausea and vomiting;Endoscopist satisfaction;Patient satisfaction; | — |
Countries
China
Contacts
Public ContactWang Junlu
The First Affiliated Hospital of Wenzhou Medical University
Outcome results
None listed